At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 324 enrolled
Drug / intervention
Dapagliflozin 10Mg Oral Tablet +1 moredrug
Likely dose
Dapagliflozin 10Mg Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin 10Mg Oral Tablet and Dapagliflozin matching placebo for Chronic Heart Failure With Preserved Systolic Function. Completed, enrolled 324 participants across 26 sites.
Detailed Summary
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart failure with preserved systolic function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartMar 2017
Primary CompletionAug 2021
TodayJul 2026
First PostedJan 24, 2017
Enrollment StartMar 1, 2017
Primary CompletionAug 13, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.4 years ago
Interventions
Dapagliflozin 10Mg Oral Tabletdrug
Dapagliflozin 10Mg Oral Tablet
Dapagliflozin matching placebodrug
Dapagliflozin matching placebo